Organization
AN2 Therapeutics
3 clinical trials
Clinical trial
A Phase 1, Single-Dose, Randomized, Placebo- and Positive-Control, Four-Way, Crossover Study for the Evaluation of the Effect of Epetraborole on QT Intervals in Healthy Adult SubjectsStatus: Completed, Estimated PCD: 2023-07-26
Clinical trial
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients With Treatment-refractory Mycobacterium Avium Complex Lung DiseaseStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
A Phase 1, Double-blind, Placebo-controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of Epetraborole Tablets Administered for up to 28 Days in Healthy Adult SubjectsStatus: Completed, Estimated PCD: 2022-02-26